{"name": "Oasmia Pharmaceutical",
 "permalink": "oasmia-pharmaceutical",
 "crunchbase_url": "http://www.crunchbase.com/company/oasmia-pharmaceutical",
 "homepage_url": "http://www.oasmia.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@oasmia.com",
 "phone_number": "+46 18 50 54 40",
 "description": "",
 "created_at": "Mon Nov 01 04:12:53 UTC 2010",
 "updated_at": "Mon Nov 01 04:15:18 UTC 2010",
 "overview": "\u003Cp\u003EOasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[135,
       58],
      "assets/images/resized/0010/8070/108070v1-max-150x150.png"],
     [[135,
       58],
      "assets/images/resized/0010/8070/108070v1-max-250x250.png"],
     [[135,
       58],
      "assets/images/resized/0010/8070/108070v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Julian",
      "last_name": "Aleksov",
      "permalink": "julian-aleksov",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Weine",
      "last_name": "Nejdemo",
      "permalink": "weine-nejdemo",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "kr75M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.oasmia.com/news.asp?c_id=182",
    "source_description": "Oasmia enters into SEK 75 million SEDA-agreement",
    "raised_amount": 75000000.0,
    "raised_currency_code": "SEK",
    "funded_year": 2010,
    "funded_month": 7,
    "funded_day": 22,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Yorkville Advisors",
         "permalink": "yorkville-advisors",
         "image":
          {"available_sizes":
            [[[150,
               94],
              "assets/images/resized/0006/0873/60873v1-max-150x150.png"],
             [[228,
               144],
              "assets/images/resized/0006/0873/60873v1-max-250x250.png"],
             [[228,
               144],
              "assets/images/resized/0006/0873/60873v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Vallongatan 1",
    "address2": "",
    "zip_code": "SE-752 28",
    "city": "Uppsala",
    "state_code": null,
    "country_code": "SWE",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:OMX"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}